Avid Bioservices Inc (CDMO)

[biopharm]

Dr. James Allison @ MD Anderson may like the Bavi + Yervoy combo trial results...which is starting in January and finally a combination that may allow Yervoy patients "true" immunotherapy without the side affects that Yervoy is associated with:

Also... Dr. Allison is quoted saying this about Yervoy: “The treatment is of the immune system, it’s not of the tumor,” -- Now, just imagine what he would have to say about Bavituximab once everyone realizes that its "FACT" that Bavi targets "flipped-PS" and may be the real target which allows 200-300%+ response rates to occur..... just needs a few more results to become known/published. Astronomical in value... : )

March 25, 2011

Yervoy, by contrast, works by essentially disabling a brake on the immune system. Because it is not specific for any type of tumor, it might conceivably be effective for many types, though this is yet to be proved in clinical trials.

“The treatment is of the immune system, it’s not of the tumor,” said James P. Allison, head of the immunology program at the Memorial Sloan-Kettering Cancer Center in New York, whose work led to the development of the drug.

The drawback is that loosening the restraints on the immune system can lead to some dangerous side effects, the most worrisome being colitis and diarrhea, but also hepatitis, endocrine dysfunction, rashes and eye problems. In the clinical trial — which involved 676 patients, 540 of whom got Yervoy — seven people died of immune-related side effects.

http://www.nytimes.com/2011/03/26/business/27drug.html?_r=0

Now, Dr. James P. Allison seemed exicted about Yervoy alone-- but I'd imagine he would be "astronomically" excited about Yervoy+Bavituximab and Bavituximab allowing an overall response rate in the ranges of 200-300% ?

Dr. Allison knows quite well what this would mean.... just as Dr. Rolf Brekken knows. I happened to see Dr. Allison is one of 3 Chairpersons who will be at "ITOC 1" ...

http://www.ecco-org.eu/ITOC1

CONFERENCE PRESIDENTS

James P. Allison (United States)

Alexander.M.M. Eggermont (France)

Volkmar Nüssler (Germany)


SCIENTIFIC COMMITTEE

Heinz-Helmut Zwierzina (Austria) – Scientific Programme Committee Chair

James P. Allison (United States)

Carsten Bokemeyer (Germany)

Ilhan Celik (Germany)

George Coukos (Switzerland)

Angus Dalgleish (United Kingdom)

Alexander.M.M. Eggermont (France)

Stefan Endres (Germany)

Bernard Fox (United States)

Thomas Gajewski (United States)

Jerome Galon (France)

Leif Hakansson (Sweden)

Robert Hawkins (United Kingdom)

Axel Hoos (United States)

Samir Khleif (United States)

Francesco Marincola (United States)

Hans-Georg Rammensee (Germany)

Pedro Romero (Switzerland)

Jose Saro (Switzerland)

Angela Shen (United States)

Christoph C. Zielinski (Austria)

Laurence Zitvogel (France)

http://www.ecco-org.eu/ITOC1

-------------------------------------------------------------

ECCO

530 followers on Linkedin

29 employees listed

http://www.linkedin.com/company/499125?trk=pro_other_cmpy

--------------------------------------------------------------

lots of interesting names at ITOC1 coming up and Peregrine will have some interesting Bavi/Yervoy data by the time this conference rolls around and these data will do nothing but add more emphasis on how vital it will be to have "Bavituximab" included in combination treatment to be considered as "true" immunotherapy.